Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2001, p. 3651-3653, Vol. 45, No. 12
Department of Internal
Medicine1 and Department of
Microbiology,4 College of Medicine, Dankook
University, Chonan, and Department of Pediatrics, Seoul
National University College of Medicine,
Seoul,3 Korea, and Edith Nourse Rogers
Memorial Veterans Hospital, Bedford, and Lahey Clinic,
Burlington, Massachusetts2
Received 23 February 2001/Returned for modification 23 June
2001/Accepted 21 August 2001
TEM-52, differing from TEM-1 by having the substitutions
Glu-104 Blood culture isolates of
Escherichia coli and Klebsiella pneumoniae
were collected from Seoul National University Children's Hospital
between 1994 and 1999. Among 16 isolates of extended-spectrum K. pneumoniae strain K28 was isolated from the blood of a
patient in a pediatric oncology unit in 1998. Analytical isoelectric focusing (7) demonstrated that strain K28 produced
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.12.3651-3653.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Evolution of TEM-Related Extended-Spectrum
-Lactamases
in Korea
![]()
ABSTRACT
Top
Abstract
Text
References
Lys, Met-182
Thr, and Gly-238
Ser, has previously been
described as the most prevalent extended-spectrum
-lactamase (ESBL)
in Korea. In a further survey, we discovered the ESBLs TEM-15, which is
like TEM-52 but lacks the substitution at residue 182, and TEM-88,
which is like TEM-52 with an additional Gly-196
Asp substitution. TEM-88 retained the activity of TEM-52 against moxalactam. Otherwise, the kinetic properties of the three ESBLs failed to show an advantage to this evolution.
![]()
TEXT
Top
Abstract
Text
References
-lactamase (ESBL)-producing E. coli and 36 isolates of
ESBL-producing K. pneumoniae, 12 and 18 isolates,
respectively, produced TEM-derived enzymes. Ten E. coli and
15 K. pneumoniae isolates produced TEM-52
-lactamase, two
K. pneumoniae strains produced TEM-15
-lactamase, and two
E. coli isolates and one K. pneumoniae isolate
produced a novel TEM-related ESBL (unpublished data). In this study, we characterized the novel TEM-type ESBL TEM-88 and compared its biochemical characteristics to those of the TEM-15 and TEM-52
-lactamases.
-lactamases with isoelectric point (pI) values of 5.6 and 7.6. The
gene for ceftazidime resistance, along with that for a pI 5.6 enzyme
and a plasmid of about 150 kb termed pMG272, was transferred by
conjugation to E. coli J53Azir (9).
For nucleotide sequencing, the blaTEM gene was
amplified with pMG272 as the template and primers T1 (5'-ATA AAA
TTC TTG AAG ACG AAA-3') and T2 (5'-GAC AGT TAC CAA TGC TTA
ATC A-3') (6). The amplified PCR product was
purified using a QIAEX gel extraction kit (Qiagen, Chatsworth, Calif.).
Both strands were sequenced using published TEM primers
(6) and a dideoxy termination cycle sequencing kit
(Perkin-Elmer Cetus, Norwalk, Conn.). The deduced amino acid
sequence of TEM-88 had four amino acid substitutions from TEM-1:
Glu-104
Lys, Met-182
Thr, Gly-196
Asp, and Gly-238
Ser (numbered according to the proposal of Ambler et al.
[1]) (Table 1). The amino
acid replacement at position 196 has not been observed in
other TEM-related ESBL genes
(http://www.lahey.org/studies/webt.htm). TEM-88 differed from
TEM-52 by 1 amino acid at position 196, and TEM-52 differed from TEM-15
by 1 amino acid at position 182 (11) (Table 1). TEM-15,
TEM-52, and TEM-88 are the only TEM-type ESBLs identified in Korea
to date. With these findings, we speculated that TEM-15 developed into
TEM-52 and that TEM-52 evolved into TEM-88 (Table 1). In order to find
out whether there was a functional advantage in such changes, we
analyzed and compared the biochemical characteristics of TEM-15,
TEM-52, and TEM-88.
TABLE 1.
Amino acid substitutions in TEM-type
-lactamases
The blaTEM-88 gene was cloned from plasmid
pMG272 with EcoRI as an 18-kb insert into the vector plasmid
pBC SK (Stratagene, La Jolla, Calif.) to produce plasmid pMG273.
Plasmid pMG273 was introduced by electroporation into E. coli XL1-Blue (Stratagene), which was used for the kinetic assays.
To represent TEM-52
-lactamase, a clinical isolate (9)
and E. coli transconjugant J53 Azir(pMG276) were
used. The blaTEM-15 gene was cloned by PCR
into the pPCR-Script Cam vector (Stratagene) from K. pneumoniae strain 23 (unpublished), and the resulting plasmid,
pMG275, was transformed by electroporation into E. coli XL1-Blue. The identity of
blaTEM-15 was reconfirmed by sequencing.
Antimicrobial susceptibility testing was performed using Etest strips
(AB Biodisk, Dalvägen, Sweden). The MICs of amoxicillin, amoxicillin-clavulanic acid, cephalothin, cefotaxime, ceftazidime, and aztreonam were similar for transformant or transconjugant E. coli strains producing TEM-15, TEM-52, or TEM-88 (Table
2). TEM-52 and TEM-88, but not TEM-15,
augmented resistance to moxalactam.
|
Kinetic assays for
-lactam hydrolysis were performed with E. coli XL1-Blue(pMG275), E. coli J53(pMG276), and
E. coli XL1-Blue(pMG273).
-Lactamase extracts were
prepared by three freeze-thaw cycles followed by Sephadex G-75
chromatography with 0.1 M phosphate buffer, pH 7.0 (Pharmacia Biotech
Inc., Piscataway, N.J.) (3). Antimicrobials used for
hydrolysis assays were benzylpenicillin, cephaloridine, cefotaxime,
moxalactam (Sigma, St. Louis, Mo.), ceftazidime (Glaxo Group
Research, Ltd., Greenford, England), and aztreonam (Bristol-Myers
Squibb, Princeton, N.J.). Initial hydrolysis rates were determined
spectrophotometrically at 37°C with 0.1 M phosphate buffer, pH
7.0. The computer program GraFit (Erithacus Software Ltd.,
Staines, United Kingdom) and linear regression using a Hanes plot
(10) were used for calculating kinetic parameters. For
benzlypenicillin, half-time analysis with a single-process curve
was used (12). Although moxalactam is stable in the
presence of most ESBLs, it was included as a substrate because TEM-52
is known to have a higher affinity for moxalactam than TEM-3 or TEM-1
(11). For moxalactam, a 50% inhibitory concentration (IC50) was determined using cephaloridine as the substrate
at five times the Km for each enzyme, because
hydrolysis rates were too small to determine. The relative values for
maximum rate of hydrolysis (Vmax) and
Km were determined as the means of two or three determinations.
All 3 enzymes showed similar biochemical characteristics such as
similar relative Vmax and
Km values for cefotaxime, ceftazidime, cephaloridine, and benzylpenicillin; more effective hydrolysis of
cefotaxime than ceftazidime; and very weak hydrolysis of aztreonam (Table 3). The IC50 of TEM-52
or TEM-88 for moxalactam was three- or fourfold lower than that
of TEM-15 (Table 3), indicating that TEM-52 had a higher affinity for
moxalactam than TEM-15 and that TEM-88 with a further
Gly-196
Asp substitution retained this property.
|
In molecular modeling, TEM residue 196 is quite far from the binding
site of the enzyme and positioned on the surface of an
-helix behind
the B3 sheet (5). Mutagenesis studies have also indicated
that residue 196 is tolerant of substitutions that have no effect on
activity (4). The Gly-196
Asp change in TEM-88 compared
to TEM-52 is thus functionally silent, similar to substitutions observed in TEM-57 and TEM-90 (2, 8). Evolution from
TEM-15 to TEM-52 to TEM-88 in Korea does not seem to be based on
improved ability to hydrolyze oxyimino-
-lactams.
Nucleotide sequence accession number. The nucleotide sequence of the blaTEM-88 gene has been submitted to GenBank under accession no. AY027590.
| |
ACKNOWLEDGMENTS |
|---|
H.P. and G.A.J. were supported in part by a Merit Review award from the VA/DoD Collaborative Research Program on Mechanisms of Emerging Pathogens.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Lahey Clinic, 41 Mall Rd., Burlington, MA 01805. Phone: (781) 744-8608. Fax: (781) 744-1264. E-mail: george.a.jacoby{at}lahey.org.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ambler, R. P., A. F. W. Coulson, J. M. Frere, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276:269-272. |
| 2. |
Bonnet, R.,
C. De Champs,
D. Sirot,
C. Chanal,
R. Labia, and J. Sirot.
1999.
Diversity of TEM mutants in Proteus mirabilis.
Antimicrob. Agents Chemother.
43:2671-2677 |
| 3. |
Bradford, P. A.,
N. V. Jacobus,
N. Bhachech, and K. Bush.
1996.
TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum -lactamases.
Antimicrob. Agents Chemother.
40:260-262[Abstract].
|
| 4. |
Huang, W.,
J. Petrosino,
M. Hirsch,
P. S. Shenkin, and T. Palzkill.
1996.
Amino acid sequence determinants of -lactamase structure and activity.
J. Mol. Biol.
258:688-703[CrossRef][Medline].
|
| 5. |
Knox, J. R.
1995.
Extended-spectrum and inhibitor-resistant TEM-type -lactamases: mutations, specificity, and three-dimensional structure.
Antimicrob. Agents Chemother.
39:2593-2601[Medline].
|
| 6. |
Mabilat, C., and S. Goussard.
1993.
PCR detection and identification of genes for extended-spectrum -lactamases, p. 553-559.
In
D. H. Persing, T. F. Smith, F. C. Tenover, and T. J. White (ed.), Diagnostic molecular microbiology. Principles and applications. American Society for Microbiology, Washington, D.C.
|
| 7. |
Matthew, M.,
A. M. Harris,
M. J. Marshall, and G. W. Ross.
1975.
The use of analytical isoelectric focusing for detection and identification of -lactamases.
J. Gen. Microbiol.
88:169-178[Medline].
|
| 8. |
Pai, H., and G. A. Jacoby.
2001.
Sequences of the NPS-1 and TLE-1 -lactamase genes.
Antimicrob. Agents Chemother.
45:2947-2948 |
| 9. |
Pai, H.,
S. Lyu,
J. H. Lee,
J. Kim,
Y. Kwon,
J.-W. Kim, and K. W. Choe.
1999.
Survey of extended-spectrum -lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea.
J. Clin. Microbiol.
37:1758-1763 |
| 10. |
Payne, D. J., and C. J. Thomson.
1998.
Molecular approaches for the detection and identification of -lactamases, p. 513-535.
In
N. Woodford, and A. P. Johnson (ed.), Molecular bacteriology: protocols and clinical applications. Humana Press, Totowa, N.J.
|
| 11. |
Poyart, C.,
P. Mugnier,
G. Quesne,
P. Berche, and P. Trieu-Cuot.
1998.
A novel extended-spectrum TEM-type -lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae.
Antimicrob. Agents Chemother.
42:108-113 |
| 12. | Wharton, C., and R. Szawelski. 1982. Half-time analysis of the integrated Michaelis equation. J. Biochem. 203:351-360. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»